Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy

In patients with acute coronary syndromes and elective PCI diabetes is independently associated with RPR [group A: OR = 2.9 (1.5-5.7) by 10 μM ADP, OR = 5.3 (1.1-27.8) by PFA-100; group B: OR = 4.0 (1.6-10.0) by 10 μM ADP]; reduced left ventricular systolic function [OR = 3.7 (2.2-6.5) by AA-PA, OR = 2.7 (1.6-4.6) by PFA-100], chronic use of aspirin [OR = 0.2 (0.1-0.4) by AA-PA, OR = 0.3 (0.2-0.5) by PFA-100] and loading dose of clopidogrel [OR = 0.2 (0.06-0.5) by 10 μM ADP] were independent variables significantly associated with RPR in patients undergoing elective PCI. In addition, inflammatory status was found to be significantly associated with RPR in both groups of patients. These results provide indications for the selection of patients for whom the evaluation of platelet reactivity could be useful.